Jaguar Health, INC DEF 14A proxy statements

Jaguar Health, Inc. is convening a Special Meeting of Stockholders to vote on critical proposals including share issuances, warrant repricing, and stock plan amendments.

Jaguar Health, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 22, 2026, to address director elections, auditor ratification, and significant equity issuances.

Jaguar Health, Inc. calls a Special Meeting to vote on increasing authorized shares, two potential reverse stock splits, and the issuance of shares for debt exchange.

Jaguar Health, Inc. calls a Special Meeting to approve the issuance of common stock related to Series N Preferred Stock exchanges and a new PIPE financing, crucial for Nasdaq compliance.

Jaguar Health, Inc. has issued a supplement to its definitive proxy statement, clarifying that Proposal 7 for its 2025 Annual Meeting is a non-routine matter under NYSE rules, impacting broker voting.

Jaguar Health, Inc. is calling its stockholders to an Annual Meeting on August 19, 2025, to vote on key proposals including the election of directors, ratification of auditors, expansion of its stock incentive plan, and approval of substantial common stock issuances from preferred stock and convertible debt exchanges.

Jaguar Health is asking stockholders to approve a reverse stock split at a ratio between 1-for-15 and 1-for-40 to meet Nasdaq's minimum bid price requirement and potentially attract a broader range of investors.

Jaguar Health issues a supplement to its definitive proxy statement, clarifying that Proposal 5 regarding adjournment of the annual meeting is now considered a non-routine matter by the NYSE, impacting broker voting rules.

Jaguar Health is holding its 2024 Annual Meeting of Stockholders to vote on key proposals including the election of a director, ratification of the auditor, executive compensation, and an amendment to the stock incentive plan.

Jaguar Health is holding a special meeting to seek stockholder approval for a reverse stock split, the issuance of common stock upon exchange of preferred stock, the issuance of shares to accredited investors, and the potential adjournment of the meeting to solicit additional proxies.